Combination of Albumin-Bound Paclitaxel and Cisplatin with Radiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma: Results from a Phase II Single-Arm Study - Takeaways - MDSpire

Combination of Albumin-Bound Paclitaxel and Cisplatin with Radiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma: Results from a Phase II Single-Arm Study

  • By

  • Shasha Yang

  • Hui Jiang

  • Liang Zhong

  • Kanjiebubi Makelike

  • Baoqing Chen

  • Mian Xi

  • Qiaoqiao Li

  • Yonghong Hu

  • Fanjun Meng

  • Yujia Zhu

  • December 1, 2025

  • 0 min

Share

  • 1

    Oesophageal cancer is highly aggressive, with squamous cell carcinoma being the predominant subtype in Chinese patients.

  • 2

    Current standard treatment for locally advanced oesophageal squamous cell carcinoma includes concurrent chemoradiotherapy, but efficacy is limited.

  • 3

    Nanoparticle albumin-bound paclitaxel shows enhanced therapeutic efficacy and safety compared to solvent-based paclitaxel.

  • 4

    A Phase II study evaluated nab-paclitaxel and cisplatin combined with radiotherapy for locally advanced oesophageal squamous cell carcinoma.

  • 5

    The study aims to assess the safety and tolerability of the treatment regimen in patients with unresectable oesophageal cancer.

Original Source(s)

Combination of Albumin-Bound Paclitaxel and Cisplatin with Radiotherapy for Locally Advanced Oesophageal Squamous Cell Carcinoma: Results from a Phase II Single-Arm Study

  • by Shasha Yang, Hui Jiang, Liang Zhong, Kanjiebubi Makelike, Baoqing Chen, Mian Xi, Qiaoqiao Li, Yonghong Hu, Fanjun Meng, Yujia Zhu

  • December 1, 2025

Related Content

Perioperative efficacy and safety of short-course radiotherapy combined with immunochemotherapy in proficient mismatch repair rectal cancer

Combination of Narrow-Margin Hepatectomy and External Beam Radiotherapy for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Fox Chase Cancer Center’s Dr. Joshua E. Meyer Named a Fellow of the American Society for Radiation Oncology

Joshua E. Meyer, MD, FASTRO, Vice Chair of Translational Research and a Professor in the Department of Radiation Oncology at Fox Chase Cancer Center, has been named a Fellow of the American Society for Radiation Oncology (ASTRO) at the organization’s 2025 Annual Meeting being held in San Francisco.

  • by

  • September 25, 2025

  • 4 min